Alzheimer's disease (AD) is the most common cause of dementia in old age and presently affects an estimated 4 million people in the U.S.A. and 0.75 million people in the U.K. It is a relentless, degenerative brain disease, characterized by progressive cognitive impairment. In the final stages of the disease, patients are often bedridden, doubly incontinent and unable to speak or to recognize close relatives. Pathological changes of Alzheimer's disease include extensive neuronal loss and the presence of numerous neurofibrillary tangles and senile plaques in the brain. The senile plaques contain amyloid fibrils derived from a 39-43-amino-acid peptide referred to as ␤-amyloid or A␤. The basic theory of the so-called 'amyloid hypothesis' is that the deposition of aggregated forms of A␤ in the brain parenchyma triggers a pathological cascade of events that leads to neurofibrillary tangle formation, neuronal loss and the associated dementia [1]. Here we discuss progress towards the identification of inhibitors of A␤ production and fibrillization.
A␤ production [5, 6] , or increased production of the longer 42-amino-acid form of A␤ (A␤42) relative to the shorter 40-amino-acid form (A␤40) [7] . The latter effect has been demonstrated in vitro in cell culture systems and in vivo in patients and in transgenic mice [7] [8] [9] [10] [11] . Synthetic A␤42 aggregates much more rapidly than A␤40 in vitro [12] , suggesting that one crucial effect of the familial AD mutations is to influence A␤ aggregation and amyloid deposition by diverting the proteolytic processing of APP towards production of longer, more amyloidogenic forms of A␤. Since all of the APP, PS1 and PS2 mutations influence either the production or properties of A␤, and since some of them give rise to familial AD with large numbers of neurofibrillary tangles (NFTs), this suggests that A␤ deposition precedes and precipitates the formation of NFTs in these patients. One puzzle remains concerning the effects of the Ala 21 →Gly mutation found in a Dutch family with a history of both cerebrovascular amyloidosis and AD. In vitro we have found that synthetic peptides incorporating this mutation have consistently refused to aggregate [4] , and this has also been reported by others [13] . However, cells transfected with this mutant form of APP do produce more A␤ than cells transfected with wild-type APP [14] . Nevertheless, the effects of this particular mutation seem worthy of further investigation.
The following observations, among others, provide further support for the amyloid hypothesis: • Down's syndrome sufferers (with three copies of chromosome 21 and hence of the APP gene) develop A␤ deposits in the brain before any other recognizable pathology, such as NFTs [15] . • Aggregated or fibrillar forms of synthetic A␤ are toxic to cultured neurons and neuronal-like cells [16] , and inhibiting A␤ aggregation blocks this toxicity; A␤ in an aggregated form also shows neurotoxic properties in vivo when injected into the brains of aged primates [17] .
• Exposure of primary neuronal cultures to fibrillar A␤ leads to tau phosphorylation [18, 19] , as does the injection of fibrillar A␤ into aged rhesus monkey cerebral cortex [17] . • Knockout of the APOE gene in the V717F PDAPP transgenic mouse model results in a dramatic reduction in brain A␤ deposition and senile plaque formation, so providing compelling evidence of a link between apolipoprotein (ApoE) and the deposition of ␤-amyloid [20] . • Mutations in the tau gene do not give rise to AD but instead give rise to frontotemporal dementia, which is characterized by the presence of tauderived inclusions without significant ␤-amyloid deposits [21] [22] [23] .
• Fibrillar protein aggregates are increasingly thought to play an important role in other neurodegenerative diseases, for example ␣-synuclein in Parkinson's disease, prion protein in the transmissible spongiform encephalopathies and Huntingtin protein in Huntington's disease [24] . The idea that aggregated forms of A␤ are responsible for neurodegeneration in AD is a basic principle of the amyloid hypothesis. The molecular mechanisms underlying the observed toxicity of A␤ to cultured neurons are not fully understood, but current evidence suggests that exposure of cells to A␤ induces the production of reactive oxygen species and free radical damage [16] , either via non-receptor-mediated intercalation of A␤ into membranes [25] , or via specific binding of A␤ to a receptor such as the RAGE receptor (receptor for advanced glycation endproducts) [26] . The peptide has also been shown to disrupt calcium homoeostasis [27, 28] and to induce apoptosis [29] . In an important series of experiments, Geula and colleagues [17] have found that the injection of fibrillar A␤ into the cerebral cortex of aged monkeys results in neuronal loss, microglial proliferation and tau phosphorylation. These effects were not seen to the same extent in younger monkeys, or in rodents, suggesting that the aged primate brain is particularly vulnerable to A␤-mediated neuronal damage. This might explain the fact that transgenic mouse models of AD with substantial deposits of A␤ can show little evidence of neuronal loss, which is frequently cited as an argument against the amyloid hypothesis.
It is important to realize that the ␤-amyloid fibrils themselves do not necessarily initiate the cascade of events that leads to neurodegeneration and dementia. The precise nature of the cytotoxic species of A␤ is unclear with small oligomers, protofibrils and higher-molecular-mass species being implicated [30] [31] [32] . A␤ that has been 'aged' for several days eventually loses its neurotoxicity, so the real culprit in AD could be an intermediate aggregate en route to mature fibril formation, such as the recently described protofibrils [13] . Indeed, the culpable form of A␤ need not be extracellular. Given data on the intracellular formation of A␤42 [33] and the detection of intracellular aggregates of A␤ [34] , it is possible that aggregation of A␤ within cells initiates NFT formation and neurodegeneration. Whether intracellular aggregates of A␤ can be regarded as 'amyloid' is a matter of semantics. Figure 1 shows an updated version of the amyloid hypothesis. 
New approaches to drug therapy
Marketed drugs for AD (acetylcholinesterase inhibitors, muscarinic agonists) are designed to increase cholinergic input to the brain, so as to enhance aspects of memory and cognition. Although it is possible that these drugs might influence the progression of AD via effects on APP processing and A␤ formation, this effect has only been demonstrated in cell culture and in brain slices and has not been reported in animal models or patients. These drugs also suffer from undesirable side effects. A prediction of the amyloid hypothesis is that drugs designed to inhibit the formation of A␤, or its aggregation into cytotoxic forms, will be effective in halting or slowing the progression of AD. The remainder of this chapter briefly reviews progress in these two areas.
Inhibitors of A␤ formation
One of the most straightforward ways to prevent the formation of A␤ would be to inhibit the proteinases (␤-and ␥-secretase) involved in its release from APP. However, despite more than 10 years of intensive research in this area, these enzymes have still not been conclusively identified. In the case of ␣-secretase, which cleaves in the middle of the A␤ sequence and so precludes A␤ formation, it is becoming increasingly likely that this enzyme is a member of the ADAMs (a disintegrin and metalloproteinase-like) family of membraneassociated zinc metalloproteinases that are similar to, but distinct from, the matrix metalloproteinases [35, 36] . The suggestion that ␣-secretase is the matrix metalloproteinase gelatinase A [37] has not been substantiated [38, 39] .
There are numerous reports claiming the identification of ␤-secretase and/or ␥-secretase. The metallopeptidase 'thimet' and the aspartyl protease cathepsin D, which were once considered as reasonable candidates for ␤-secretase, now appear unlikely [40, 41] . In the case of ␥-secretase, the situation is complicated by the fact that there may be different enzymes responsible for the generation of A␤40 and A␤42 [42, 43] , and this has been highlighted by the finding that A␤40 and A␤42 are formed in different subcellular compartments [33] . Again, the question of whether one or more ␥-secretases exist has not been clearly resolved. Two interesting possibilities that have arisen recently are that the metalloproteinase S2P or the presenilin PS1 may in fact be ␥-secretase. The former candidate was identified through similarities between the proteolytic cleavage of APP and cleavage of the sterol regulatory element binding protein [44] [45] [46] . However, the fact that production of A␤40 and A␤42 is the same in CHO cell variant M19 cells that lack S2P as it is in wild-type cells, indicates that S2P cannot be ␥-secretase [44, 45] . Mutagenesis of two transmembrane aspartate residues in PS1 has been found to abolish APP cleavage at the ␥-secretase site, suggesting that PS1 may be ␥-secretase [47] . However, these data are not conclusive as a role for PS1 upstream of the actual cleavage event (e.g. in presenting ␥-secretase to its APP substrate) cannot be ruled out. One possibility is that PS1 interacts with ␥-secretase and that the aspartate residues mentioned above are important in modulating this interaction. In this context, it is interesting to note that recent independent studies, which have been the subject of commercial patent applications, have identified two different serine proteases that have been picked out as interacting partners with PS1 in the yeast two-hybrid system [48, 49] . The relationship of these proteases to ␥-secretase is unknown.
In the absence of clear data on the identity of the secretases, an alternative approach to the identification of secretase inhibitors has been to test the effects of various known protease inhibitors on A␤ production from whole cells in culture. In this way, several independent groups have found that certain peptide aldehydes, in particular Cbz-Phe-Leu-H (MDL-28170), Cbz-Leu-LeuLeu-H (calpain inhibitor 1), Cbz-Leu-Leu-Nle-H, and Cbz-Leu-Nle-H (calpeptin), can inhibit A␤ formation [42, 43, [50] [51] [52] . These compounds have been proposed as inhibitors of ␥-secretase, based on the fact that they block p3 (residues 17-40/42 of A␤) as well as A␤ formation, with little effect on the release of sAPP␣ or sAPP␤ (secreted forms of APP), and also inhibit the formation of A␤ from cells transfected with the C-terminal 100 amino acids of APP. However, since these inhibitors were identified in whole-cell systems, their effects on APP processing could be indirect. Therefore, their precise molecular target has not been established. Peptide aldehydes of this type are known to be potent inhibitors of both cysteine proteases (such as the calpains) and serine proteases. It has recently been shown that peptide boronic acids, which are inhibitors of serine proteases only, are considerably more potent inhibitors of A␤ formation than their parent aldehydes [53] (Figure 2 ). The boronates showed very similar properties to the aldehydes, suggesting that they both inhibit A␤ formation by the same mechanism. At active concentrations of these inhibitors, there was little or no effect on MTT turnover (a marker of mitochondrial dehydrogenase activity), or on the production of sAPP␣, indicating that these compounds do not inhibit A␤ by an overtly toxic effect (Figure 2) . However, it was noted with all of the effective inhibitors that there was a change in cell morphology and adhesion (rounding up and detachment from plates) at the higher concentrations of inhibitor and over prolonged exposure times (Ͼ18 hours). This suggests that these compounds might be inhibiting A␤ formation via a more subtle, indirect mechanism. The activity of these compounds as inhibitors of A␤ production was shown to correlate remarkably well with their potency as inhibitors of the chymotrypsin-like activity of the proteasome (CLIP), suggesting that they exert their effects on A␤ through inhibition of CLIP [53] . Proteasomes are involved in the destruction of aberrant proteins, progression through the cell cycle, tumorigenesis and inflammation, and they also play an important role in antigen presentation. The 26S proteasome/ubiquitin system has been shown to be capable of degrading not only cytoplasmic proteins, but also certain membrane-spanning proteins, including mutant proteins found in the endoplasmic reticulum (ER) such as the cystic fibrosis transmembrane regulatory protein [54] . The precise molecular mechanism of the latter process is unclear, but presumably it involves proteasomes attached to the cytoplasmic side of the ER membrane. Thus, the possibility that the proteasome is involved directly in the proteolytic processing of APP cannot be entirely ruled out. Regardless of the precise mechanism of action of these aldehyde and boronate inhibitors, it is clear that this type of compound is unlikely to be a viable therapeutic agent for AD since inhibition of the proteasome is likely to have unacceptable side effects/toxicity.
Wolfe and colleagues have recently described a series of difluoroketones that also appear to be inhibitors of ␥-secretase [55, 56] . This was demonstrated not only in a cell-based assay system but also in a cell-free membrane system, which makes these compounds more convincing as direct-acting ␥-secretase inhibitors. Some of the effective compounds proved to be potent inhibitors of the aspartyl protease cathepsin D, but poor inhibitors of the cysteine protease calpain 1. This rules out the possibility that ␥-secretase is a calpain-like enzyme. However, from the published data [56] it is clear that there was a very poor correlation between the potency of these compounds as cathepsin D inhibitors and their activity as inhibitors of A␤ production. This supports the previous conclusion from cathepsin D knockout mice that this enzyme cannot be ␥-secretase [41] . However, it is possible that ␥-secretase is another aspartyl protease. This is certainly intriguing given the link between the two aspartyl residues in PS-1 and the activity of ␥-secretase [47] . We are currently investigating the effects of these difluoroketone inhibitors on CLIP.
Inhibitors of A␤ aggregation
Known details of the A␤ fibrillogenesis process are drawn almost entirely from work with synthetic peptides [57, 58] . Peptide fragments of A␤ from 9-43 amino acid residues in length will aggregate to form fibrils, with the longer peptides tending to produce fibrils that are most similar in appearance to amyloid in the brain itself. The mature ␤-amyloid fibril appears to be constructed from a small number of 'protofibrils' arranged in lateral association, with the A␤ molecules within the protofibrils taking up the cross-␤ configuration that is typical of all amyloids [57] . Data on the mechanism and kinetics of A␤ fibrillization are consistent with a nucleation-dependent model of fibril formation [12, 59] where soluble peptide monomers (or dimers) combine to form 'nuclei' which themselves combine to form an early fibrillar intermediate or protofibril, with mature amyloid fibrils probably being formed by the lateral association of protofibrils [57] [58] [59] [60] [61] (Figure 3) . The slow formation of nuclei is the rate-limiting step in this process, but this step can be bypassed or greatly accelerated by the presence of amyloid 'seed' in the form of preaggregated A␤. Hence, control of nucleation-dependent oligomer formation may be an important determinant of disease development in AD.
A number of compounds have now been described which can inhibit A␤ fibrillization. These include ␤-cyclodextrin, rifamycins, laminin, a series of charged sulphonates, nicotine, melatonin, the anthracycline 4Ј-deoxy-4Ј-iododoxorubicin (IDOX) and short synthetic peptide fragments based on the central hydrophobic region of A␤ [62, 63] . There have been no reports of the effects of any of these compounds on A␤ deposition in the available transgenic mouse models of AD, but Soto and colleagues [64] have claimed that a synthetic '␤-sheet breaker peptide' can prevent A␤ deposition when co-injected with A␤ directly into rat brain. However, it is not clear from this study whether A␤ aggregation was actually inhibited in vivo or prior to/during the course of the injection. More recently, it has been reported that immunization of V717F PDAPP transgenic mice with aggregated forms of A␤42 can block and even reverse the formation of ␤-amyloid fibrils and senile plaques [65] . It is impossible to determine in this model whether blocking the formation of A␤ fibrils prevents neurodegeneration because significant neuronal loss has not been detected in these mice. As noted above, this is most likely due to rodent brains being inherently less sensitive than primate brains to the toxic effects of A␤ aggregates. The mechanism by which ␤-amyloid deposition is blocked and reversed in the immunized mice is unknown, but it has been shown that the formation of synthetic A␤ fibrils can be inhibited and even reversed by anti-A␤ antibodies [66] [67] [68] [69] suggesting that antibodies induced by the injections might have the same effect. This possibility will only serve to accelerate the search for brain-penetrant, low-molecular-mass inhibitors of A␤ aggregation. We have recently been involved in the study of a number of benzofuran derivatives (Figure 4 ) that have been identified as inhibitors of A␤ aggregation [70] [71] [72] . These compounds have been shown to inhibit A␤ fibril formation by means of a standard Congo Red binding assay, and also as assessed by a novel sandwich immunoassay that detects only aggregated forms of A␤ [32, 72] . The latter assay is based on the capture of synthetic A␤ peptide with a monoclonal antibody (mAb) directed at residues 1-16 (e.g. the commercially available 6E10), followed by detection with a biotinylated form of the same mAb. This immunoassay has been shown to give a strong signal only when the A␤ peptide has been incubated under conditions in which some aggregation occurs [32, 72] . This is presumably because multiple copies of the same mAb epitope are available for capture and detection only when the A␤ is in an aggregated state ( Figure 5) . Interestingly, we have demonstrated, by dot blotting, that antibodies to the N-terminus of A␤ react weakly with A␤40 monomers or dimers, but immunoreactivity is greatly enhanced following peptide incubation and aggregation [73] . This might also explain the fact that a sandwich immunoassay configured with two antibodies directed at the N-terminus of A␤ detects only aggregated forms of A␤. The biotinylated secondary antibody is detected with streptavidin-europium, with quantification by the DELFIA system (delayed enhanced lanthanide fluorescence immunoassay). The precise point of intervention of the benzofuran inhibitors along the A␤ aggregation pathway is unknown, but these compounds have been shown to block the cytotoxicity of A␤ [72] and so appear to act at a point prior to formation of the cytotoxic amyloid species. Unlike many of the other reported anti-aggregation inhibitors, these benzofurans are responsive to chemical modification using a high-speed parallel synthetic approach. Interestingly, they are similar in structure to amiodarone, an iodinated benzofuran derivative that is a potent, orally bioavailable drug for heart arrhythmia and angina [74] . Amiodarone is also known to be a brain penetrant but we have found that amiodarone itself is a poor inhibitor of A␤ aggregation (D. Allsop and Y. Davies, unpublished work). However, if the more active benzofuran derivatives have a similar bioavailability profile to amiodarone, then they may be suitable as test compounds to determine if it is feasible to inhibit A␤ aggregation with a small molecule inhibitor in a transgenic mouse model. With this in mind, we have developed a novel synthetic route to the target benzofuran inhibitor 3- (Figure 4) . In an effort to obtain more potent inhibitors, we are developing a combinatorial approach towards the synthesis of other related benzofurans, which will be tested against a variety of amyloid-forming proteins and peptides.
Fluorescence anisotropy as a method of monitoring A␤ aggregation
We have also been interested in developing more sensitive methods than those available at present for monitoring A␤ aggregation and for determining the point of intervention of inhibitors in the A␤ aggregation and fibril assembly pathway (Figure 3) . One technique that we have begun to look at is fluorescence anisotropy, which can be used to determine the rate at which a fluorescent species tumbles in solution. Since the rate of reorientation of a particle is a function of its size, fluorescence anisotropy measurements, particularly time-resolved experiments, offer a very sensitive and informative means of interrogating interactions between molecules [75] [76] [77] . We have carried out some preliminary experiments with the fluorescein-labelled form of ␤-amyloid (so-called fluo-␤-amyloid) recently marketed by New England Nuclear. In a time-resolved anisotropy experiment, a pulse of polarized light is used to excite (a proportion of) those fluorescent molecules which are orientated within the plane of polarization at the instant of excitation. Fluorescence emitted shortly after absorption will be highly polarized. However, since the molecules reorientate to regain a random distribution within the system, the fluorescence observed as time progresses becomes less and less polarized. Once randomization is complete, light emitted from the molecular assembly is unpolarized. The degree of polarization of the fluorescence, expressed as the anisotropy, r, will decay from a characteristic initial value to zero, at a rate determined by the rate at which molecular reorientation occurs. The rate of anisotropy decay and, thence, of molecular motion, can be expressed as a 'correlation time', c . The more slowly the particle tumbles, the longer the value of c . Figure 6 (a) shows that the anisotropy of the fluorescence from a dilute solution (1 M) of fluorescently labelled ␤-peptide on its own decays rapidly to zero ( c~1 ns). Upon addition of unlabelled peptide, at a concentration which will induce aggregation (in this case 125 M), a much more slowly decaying component appears and the anisotropy, r, no longer attains zero within the time range over which fluorescence can be observed. The relative magnitude of this longer-lived, i.e. greater c value, component of the anisotropy increases with incubation time and this component is clearly associated with the presence of aggregated forms of A␤ and amyloid fibrils in the system (Figure 6b ). These results demonstrate that fluorescently labelled A␤ is incorporated into synthetic ␤-amyloid fibrils and that this process can be monitored very effectively and at early time points by measuring changes in fluorescence polarization. There are reports in the literature involving the use of energy transfer measurements or fluorescence correlation spectroscopy to study A␤ peptide aggregation [78] [79] [80] [81] but there are no reported studies using fluorescence anisotropy for this purpose. We now intend to develop the method further and to investigate the effects of aggregation inhibitors in this system.
Conclusion
Recent developments in understanding of the genetics of the 'tauopathies' and the emergence of protein aggregation as a common theme in various neurodegenerative disorders such as AD, Parkinson's disease, prion disease and Huntington's disease, have only acted to strengthen the amyloid hypothesis. The same applies to the finding of a clear link between the presence of ApoE and the deposition of A␤ in the brains of transgenic mice, and the demonstration that the aged primate brain is particularly vulnerable to the toxic effects of A␤. However, emphasis has now shifted away from mature amyloid fibrils and towards intermediates in the fibril assembly pathway, since it is becoming increasingly likely that the latter are responsible for the neurotoxic properties of A␤. It has been argued that these intermediates cannot be regarded as 'amyloid' if their effects are due to accumulation within cells, but in our opinion this is purely a matter of semantics and is, therefore, a sterile argument. The dramatic demonstration that immunization of transgenic mice with A␤ can block and even reverse the formation of senile plaques suggests that the time is fast approaching when the amyloid hypothesis will be tested in human patients.
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